# Switchpoint Bio

> Developing blood-based DNA-methylation profiling and AI to monitor disease biology and treatment response for drug developers.

## Why it is interesting

A company-issued November 11 Finnish release reports $5.3M pre-seed financing, including $5M from Treehouse Delmar Investments. Its assay is moving toward clinical and industry validation rather than a proven or approved diagnostic. A longitudinal blood test could potentially reduce the burden of repeated complex sampling, but that remains an unproven commercial claim.

## Profile

- **Latest funding:** Pre-seed (issuer release dateline; precise legal close unknown) — $5.3M (November 10, 2026)
- **Latest known valuation:** Undisclosed (November 10, 2026)
- **Total disclosed equity funding:** $5.3M
- **Stage:** pre-seed
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-11
- **Latest funding investors:** Treehouse Delmar Investments

## Key facts

- Original issuer release published Nov 11, 2026 12:45 EET, with internal Nov 10 dateline; no legal close date stated.
- $5.3M pre-seed total; Treehouse Delmar contributes $5M of this total, not in addition.
- Research platform uses targeted DNA methylation, single-cell reference data and AI; clinical and industry validation is pending.

## Funding history

- Pre-seed (issuer release dateline; precise legal close unknown) · $5.3M · November 10, 2026
  Source: https://www.sttinfo.fi/tiedote/72494086/switchpoint-bio-kerasi-53-miljoonaa-dollaria-tavoitteena-paljastaa-laakehoitojen-biologiset-vaikutukset-verinaytteesta?lang=fi&publisherId=69831237

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 11, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/switchpoint-bio